Author:
Iihara Hirotoshi,Abe Masakazu,Wada Makoto,Iino Keiko,Akechi Tatsuo,Imamura Chiyo K.,Okuyama Ayako,Ozawa Keiko,Kim Yong-Il,Sasaki Hidenori,Satomi Eriko,Takeda Masayuki,Tanaka Ryuhei,Nakajima Takako Eguchi,Nakamura Naoki,Nishimura Junichi,Noda Mayumi,Hayashi Kazumi,Higashi Takahiro,Boku Narikazu,Matsumoto Koji,Matsumoto Yoko,Okita Kenji,Yamamoto Nobuyuki,Aogi Kenjiro
Abstract
Abstract
Background
The Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis 2023 was extensively revised to reflect the latest advances in antineoplastic agents, antiemetics, and antineoplastic regimens. This update provides new evidence on the efficacy of antiemetic regimens.
Methods
Guided by the Minds Clinical Practice Guideline Development Manual of 2017, a rigorous approach was used to update the guidelines; a thorough literature search was conducted from January 1, 1990, to December 31, 2020.
Results
Comprehensive process resulted in the creation of 13 background questions (BQs), 12 clinical questions (CQs), and three future research questions (FQs). Moreover, the emetic risk classification was also updated.
Conclusions
The primary goal of the present guidelines is to provide comprehensive information and facilitate informed decision-making, regarding antiemetic therapy, for both patients and healthcare providers.
Publisher
Springer Science and Business Media LLC